Characterization of Androgen Receptor in Breast Cancer Tissue.
Amy Vora, Eric Siegel, Leah Hennings, Lori Talley, Soheila Korourian. University of Arkansas for Medical Sciences, Little Rock
Background: The role of androgens and androgen receptors in breast cancer remains unclear. The purpose of this study was to investigate the correlation of androgen-receptor expression with breast cancer survival.
Design: Tissue array blocks from 150 women diagnosed with invasive breast carcinoma were used. These patients were divided into three groups: The D5 group (N=50) were patients who died of cancer within 5 years of initial diagnosis, most of whom had stage III and IV at the time of initial diagnosis. The remaining 100 patients had stage II cancer at the time of initial presentation, and were divided into the T2N1 group (1-3 positive lymph nodes, N=52) or the T2N0 group (negative lymph nodes, N=48). Immunohistochemical (IHC) staining for androgen receptor (AR). The result of estrogen receptor (ER) and progesterone receptor (PR) was also available.
Results: 36 out of 48 patients with T2N0 were AR positive, as were 43/52 T2N1 tumors, compared to 27/50 D5 patients. D5 patients showed a significantly lower level of expression compared to T2N0 and T2N1 patients (p<.0001). There was no significant difference in average AR expression between T2N0, T2N1 populations (p=.0746). There was a significant association between average AR expression and ER expression (p<.0001). As the ER intensity increased, the average AR score increased as well. AR expression also correlated with PR intensity (p<.0001).
Conclusions: D5 tumors expressed significantly lower level of androgen receptor. This suggests that androgens and androgen receptors may play a role in cancer progression.
Tuesday, March 1, 2011 1:00 PM
Poster Session IV # 22, Tuesday Afternoon